Nutraceuticals for prostate cancer chemoprevention: from molecular mechanisms to clinical application

Bibliography

• Thompson I, Tangen C, Tolcher A, et al. Association of African-American ethnic background with survival in men with metastatic prostate cancer. J Natl Cancer Inst 2001;93:219-25
   PubMed Web of Science ®Google Scholar
• Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin 2011;61:69-90
   PubMed Web of Science ®Google Scholar
• Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013;63:11-30
   PubMed Web of Science ®Google Scholar
• Sorensen KD, Orntoft TF. Discovery of prostate cancer biomarkers by microarray gene expression profiling. Expert Rev Mol Diagn 2010;10:49-64
   PubMed Web of Science ®Google Scholar
• Roehrborn CG, Black LK. The economic burden of prostate cancer. BJU Int 2011;108:806-13
   PubMed Web of Science ®Google Scholar
• Bemis DL, Katz AE, Buttyan R. Clinical trials of natural products as chemopreventive agents for prostate cancer. Expert Opin Investig Drugs 2006;15:1191-200
   PubMed Web of Science ®Google Scholar
• Van Poppel H, Tombal B. Chemoprevention of prostate cancer with nutrients and supplements. Cancer Manag Res 2011;3:91-100
   PubMedGoogle Scholar
• Parnes HL, House MG, Tangrea JA. Prostate cancer prevention: strategies for agent development. Curr Opin Oncol 2013;25:242-51
   PubMed Web of Science ®Google Scholar
• Canby-Hagino ED, Thompson IM. Mechanisms of disease: prostate cancer–a model for cancer chemoprevention in clinical practice. Nat Clin Pract Oncol 2005;2:255-61
   PubMedGoogle Scholar
• Violette PD, Saad F. Chemoprevention of prostate cancer: myths and realities. J Am Board Fam Med 2012;25:111-19
   PubMed Web of Science ®Google Scholar
• Lippert MC, McClain R, Boyd JC, et al. Alternative medicine use in patients with localized prostate carcinoma treated with curative intent. Cancer 1999;86:2642-8
   PubMed Web of Science ®Google Scholar
• Nam RK, Fleshner N, Rakovitch E, et al. Prevalence and patterns of the use of complementary therapies among prostate cancer patients: an epidemiological analysis. J Urol 1999;161:1521-4
   PubMed Web of Science ®Google Scholar
• Kalra EK. Nutraceutical–definition and introduction. AAPS PharmSci 2003;5:E25
   PubMed Web of Science ®Google Scholar
• Rittmaster RS. Chemoprevention of prostate cancer. Acta Oncol (Madr) 2011;50(Suppl 1):127-36
   Google Scholar
• Madu CO, Lu Y. Novel diagnostic biomarkers for prostate cancer. J Cancer 2010;1:150-77
   PubMed Web of Science ®Google Scholar
• Nelson WG, De Marzo AM, Isaacs WB. Prostate cancer. N Engl J Med 2003;349:366-81
   PubMed Web of Science ®Google Scholar
• De Marzo AM, Platz EA, Sutcliffe S, et al. Inflammation in prostate carcinogenesis. Nat Rev Cancer 2007;7:256-69
   PubMed Web of Science ®Google Scholar
• Sciarra A, Di Silverio F, Salciccia S, et al. Inflammation and chronic prostatic diseases: evidence for a link? Eur Urol 2007;52:964-72
   PubMed Web of Science ®Google Scholar
• Boyd LK, Mao X, Lu YJ. The complexity of prostate cancer: genomic alterations and heterogeneity. Nat Rev Urol 2012;9:652-64
   PubMed Web of Science ®Google Scholar
• Cimino S, Sortino G, Favilla V, et al. Polyphenols: key issues involved in chemoprevention of prostate cancer. Oxid Med Cell Longev 2012;2012:632959
   PubMed Web of Science ®Google Scholar
• Ho E, Beaver LM, Williams DE, et al. Dietary factors and epigenetic regulation for prostate cancer prevention. Adv Nutr 2011;2:497-510
   PubMed Web of Science ®Google Scholar
• Nelson WG. Prostate cancer prevention. Curr Opin Urol 2007;17:157-67
   PubMed Web of Science ®Google Scholar
• Andriole G, Bruchovsky N, Chung LW, et al. Dihydrotestosterone and the prostate: the scientific rationale for 5alpha-reductase inhibitors in the treatment of benign prostatic hyperplasia. J Urol 2004;172:1399-403
   PubMed Web of Science ®Google Scholar
• Tindall DJ, Rittmaster RS. The rationale for inhibiting 5alpha-reductase isoenzymes in the prevention and treatment of prostate cancer. J Urol 2008;179:1235-42
   PubMed Web of Science ®Google Scholar
• Liao S, Hiipakka RA. Selective inhibition of steroid 5 alpha-reductase isozymes by tea epicatechin-3-gallate and epigallocatechin-3-gallate. Biochem Biophys Res Commun 1995;214:833-8
   PubMed Web of Science ®Google Scholar
• Halliwell B. Free radicals and antioxidants: updating a personal view. Nutr Rev 2012;70:257-65
   PubMed Web of Science ®Google Scholar
• Cui X. Reactive oxygen species: the Achilles' heel of cancer cells? Antioxid Redox Signal 2012;16:1212-14
   PubMed Web of Science ®Google Scholar
• Sporn MB, Liby KT. Cancer chemoprevention: scientific promise, clinical uncertainty. Nat Clin Pract Oncol 2005;2:518-25
   PubMedGoogle Scholar
• Gupta SC, Hevia D, Patchva S, et al. Upsides and downsides of reactive oxygen species for cancer: the roles of reactive oxygen species in tumorigenesis, prevention, and therapy. Antioxid Redox Signal 2012;16:1295-322
   PubMed Web of Science ®Google Scholar
• Kwak MK, Kensler TW. Targeting nrf2 signaling for cancer chemoprevention. Toxicol Appl Pharmacol 2009;244:66-76
   PubMed Web of Science ®Google Scholar
• Ho E, Beaver LM, Williams DE, et al. Dietary factors and epigenetic regulation for prostate cancer prevention. Adv Nutr 2011;2:497-510
   PubMed Web of Science ®Google Scholar
• Ho E, Clarke JD, Dashwood RH. Dietary sulforaphane, a histone deacetylase inhibitor for cancer prevention. J Nutr 2009;139:2393-6
   PubMed Web of Science ®Google Scholar
• Chiyomaru T, Yamamura S, Zaman MS, et al. Genistein suppresses prostate cancer growth through inhibition of oncogenic microrna-151. PLoS One 2012;7(8):e43812
   PubMed Web of Science ®Google Scholar
• Luo J-H, Ding Y, Chen R, et al. Genome-wide methylation analysis of prostate tissues reveals global methylation patterns of prostate cancer. Am J Pathol 2013;182(6):2028-36
   PubMed Web of Science ®Google Scholar
• Parasramka MA, Ho E, Williams DE, et al. Micrornas, diet, and cancer: new mechanistic insights on the epigenetic actions of phytochemicals. Mol Carcinog 2012;51:213-30
   PubMed Web of Science ®Google Scholar
• Abbas A, Gupta S. The role of histone deacetylases in prostate cancer. Epigenetics 2008;3:300-9
   PubMed Web of Science ®Google Scholar
• Gravina GL, Ranieri G, Muzi P, et al. Increased levels of DNA methyltransferases are associated with the tumorigenic capacity of prostate cancer cells. Oncol Rep 2013;29:1189-95
   PubMed Web of Science ®Google Scholar
• Yu SW, Khor TO, Cheung KL, et al. Nrf2 expression is regulated by epigenetic mechanisms in prostate cancer of tramp mice. PLoS One 2010;5(1):e8579
   PubMedGoogle Scholar
• Yi B, Piazza GA, Su X, et al. Microrna and cancer chemoprevention. Cancer Prev Res (Phila) 2013;6:401-9
   PubMed Web of Science ®Google Scholar
• Yang CS, Li G, Yang Z, et al. Cancer prevention by tocopherols and tea polyphenols. Cancer Lett 2013; Epub ahead of print
   Web of Science ®Google Scholar
• Yang CS, Wang X, Lu G, et al. Cancer prevention by tea: animal studies, molecular mechanisms and human relevance. Nat Rev Cancer 2009;9:429-39
   PubMed Web of Science ®Google Scholar
• Suzuki K, Yahara S, Hashimoto F, et al. Inhibitory activities of (-)-epigallocatechin-3-o-gallate against topoisomerases i and ii. Biol Pharm Bull 2001;24:1088-90
   PubMed Web of Science ®Google Scholar
• Thakur VS, Gupta K, Gupta S. Green tea polyphenols causes cell cycle arrest and apoptosis in prostate cancer cells by suppressing class i histone deacetylases. Carcinogenesis 2012;33:377-84
   PubMed Web of Science ®Google Scholar
• Kurahashi N, Sasazuki S, Iwasaki M, et al. Green tea consumption and prostate cancer risk in Japanese men: a prospective study. Am J Epidemiol 2008;167:71-7
   PubMed Web of Science ®Google Scholar
• Bettuzzi S, Brausi M, Rizzi F, et al. Chemoprevention of human prostate cancer by oral administration of green tea catechins in volunteers with high-grade prostate intraepithelial neoplasia: a preliminary report from a one-year proof-of-principle study. Cancer Res 2006;66:1234-40
   PubMed Web of Science ®Google Scholar
• Brausi M, Rizzi F, Bettuzzi S. Chemoprevention of human prostate cancer by green tea catechins: two years later. A follow-up update. Eur Urol 2008;54:472-3
   PubMed Web of Science ®Google Scholar
• Jian L, Xie LP, Lee AH, et al. Protective effect of green tea against prostate cancer: a case-control study in southeast china. Int J Cancer 2004;108:130-5
   PubMed Web of Science ®Google Scholar
• Nguyen MM, Ahmann FR, Nagle RB, et al. Randomized, double-blind, placebo-controlled trial of polyphenon e in prostate cancer patients before prostatectomy: evaluation of potential chemopreventive activities. Cancer Prev Res (Phila) 2012;5:290-8
   PubMed Web of Science ®Google Scholar
• Wang P, Aronson WJ, Huang M, et al. Green tea polyphenols and metabolites in prostatectomy tissue: implications for cancer prevention. Cancer Prev Res (Phila) 2010;3:985-93
   PubMed Web of Science ®Google Scholar
• Jatoi A, Ellison N, Burch PA, et al. A phase ii trial of green tea in the treatment of patients with androgen independent metastatic prostate carcinoma. Cancer 2003;97:1442-6
   PubMed Web of Science ®Google Scholar
• Choan E, Segal R, Jonker D, et al. A prospective clinical trial of green tea for hormone refractory prostate cancer: an evaluation of the complementary/alternative therapy approach. Urol Oncol 2005;23:108-13
   PubMed Web of Science ®Google Scholar
• Clinical trials: US NIH, ClinicalTrials.gov
   Google Scholar
• Strick R, Strissel PL, Borgers S, et al. Dietary bioflavonoids induce cleavage in the mll gene and may contribute to infant leukemia. Proc Natl Acad Sci USA 2000;97:4790-5
   PubMed Web of Science ®Google Scholar
• Plichart M, Menegaux F, Lacour B, et al. Parental smoking, maternal alcohol, coffee and tea consumption during pregnancy and childhood malignant central nervous system tumours: the escale study (sfce). Eur J Cancer Prev 2008;17:376-83
   PubMed Web of Science ®Google Scholar
• Laviano A, Rianda S, Molfino A, et al. Omega-3 fatty acids in cancer. Curr Opin Clin Nutr Metab Care 2013;16:156-61
   PubMed Web of Science ®Google Scholar
• Chua ME, Sio MC, Sorongon MC, et al. Relationship of dietary intake of omega-3 and omega-6 fatty acids with risk of prostate cancer development: a meta-analysis of prospective studies and review of literature. Prostate Cancer 2012;2012:826254
   PubMedGoogle Scholar
• Berquin IM, Min Y, Wu R, et al. Modulation of prostate cancer genetic risk by omega-3 and omega-6 fatty acids. J Clin Invest 2007;117:1866-75
   PubMed Web of Science ®Google Scholar
• Kobayashi N, Barnard RJ, Henning SM, et al. Effect of altering dietary omega-6/omega-3 fatty acid ratios on prostate cancer membrane composition, cyclooxygenase-2, and prostaglandin e2. Clin Cancer Res 2006;12:4662-70
   PubMed Web of Science ®Google Scholar
• Aronson WJ, Kobayashi N, Barnard RJ, et al. Phase ii prospective randomized trial of a low-fat diet with fish oil supplementation in men undergoing radical prostatectomy. Cancer Prev Res (Phila) 2011;4:2062-71
   PubMed Web of Science ®Google Scholar
• Berquin IM, Edwards IJ, Chen YQ. Multi-targeted therapy of cancer by omega-3 fatty acids. Cancer Lett 2008;269:363-77
   PubMed Web of Science ®Google Scholar
• Szymanski KM, Wheeler DC, Mucci LA. Fish consumption and prostate cancer risk: a review and meta-analysis. Am J Clin Nutr 2010;92:1223-33
   PubMed Web of Science ®Google Scholar
• Gerber M. Omega-3 fatty acids and cancers: a systematic update review of epidemiological studies. Br J Nutr 2012;107(Suppl 2):S228-39
   PubMed Web of Science ®Google Scholar
• Terry P, Lichtenstein P, Feychting M, et al. Fatty fish consumption and risk of prostate cancer. Lancet 2001;357:1764-6
   PubMed Web of Science ®Google Scholar
• Aronson WJ, Glaspy JA, Reddy ST, et al. Modulation of omega-3/omega-6 polyunsaturated ratios with dietary fish oils in men with prostate cancer. Urology 2001;58:283-8
   PubMed Web of Science ®Google Scholar
• Demark-Wahnefried W, Robertson CN, Walther PJ, et al. Pilot study to explore effects of low-fat, flaxseed-supplemented diet on proliferation of benign prostatic epithelium and prostate-specific antigen. Urology 2004;63:900-4
   PubMed Web of Science ®Google Scholar
• Brasky TM, Darke AK, Song X, et al. Plasma phospholipid fatty acids and prostate cancer risk in the select trial. J Natl Cancer Inst 2013;105(15):1132-41
   PubMed Web of Science ®Google Scholar
• Clarke JD, Dashwood RH, Ho E. Multi-targeted prevention of cancer by sulforaphane. Cancer Lett 2008;269:291-304
   PubMed Web of Science ®Google Scholar
• Juge N, Mithen RF, Traka M. Molecular basis for chemoprevention by sulforaphane: a comprehensive review. Cell Mol Life Sci 2007;64:1105-27
   PubMed Web of Science ®Google Scholar
• Kolonel LN, Hankin JH, Whittemore AS, et al. Vegetables, fruits, legumes and prostate cancer: a multiethnic case-control study. Cancer Epidemiol Biomarkers Prev 2000;9:795-804
   PubMed Web of Science ®Google Scholar
• Cohen JH, Kristal AR, Stanford JL. Fruit and vegetable intakes and prostate cancer risk. J Natl Cancer Inst 2000;92:61-8
   PubMed Web of Science ®Google Scholar
• Shapiro TA, Fahey JW, Dinkova-Kostova AT, et al. Safety, tolerance, and metabolism of broccoli sprout glucosinolates and isothiocyanates: a clinical phase i study. Nutr Cancer 2006;55:53-62
   PubMed Web of Science ®Google Scholar
• Kensler TW, Chen JG, Egner PA, et al. Effects of glucosinolate-rich broccoli sprouts on urinary levels of aflatoxin-DNA adducts and phenanthrene tetraols in a randomized clinical trial in He Zuo township, Qidong, People's Republic of China. Cancer Epidemiol Biomarkers Prev 2005;14:2605-13
   PubMed Web of Science ®Google Scholar
• Myzak MC, Tong P, Dashwood WM, et al. Sulforaphane retards the growth of human pc-3 xenografts and inhibits HDAC activity in human subjects. Exp Biol Med (Maywood) 2007;232:227-34
   PubMed Web of Science ®Google Scholar
• Traka M, Gasper AV, Melchini A, et al. Broccoli consumption interacts with gstm1 to perturb oncogenic signalling pathways in the prostate. PLoS One 2008;3:e2568
   PubMed Web of Science ®Google Scholar
• Favus MJ, Langman CB. Evidence for calcium-dependent control of 1,25-dihydroxyvitamin d3 production by rat kidney proximal tubules. J Biol Chem 1986;261:11224-9
   PubMedGoogle Scholar
• DeLuca HF. Overview of general physiologic features and functions of vitamin d. Am J Clin Nutr 2004;80:1689S-96S
   PubMed Web of Science ®Google Scholar
• Berger U, Wilson P, McClelland RA, et al. Immunocytochemical detection of 1,25-dihydroxyvitamin d receptors in normal human tissues. J Clin Endocrinol Metab 1988;67:607-13
   PubMed Web of Science ®Google Scholar
• Wang Y, Zhu J, DeLuca HF. Where is the vitamin d receptor? Arch Biochem Biophys 2012;523:123-33
   PubMed Web of Science ®Google Scholar
• Wang X, Studzinski GP. Activation of extracellular signal-regulated kinases (erks) defines the first phase of 1,25-dihydroxyvitamin d3-induced differentiation of hl60 cells. J Cell Biochem 2001;80:471-82
   PubMed Web of Science ®Google Scholar
• Shabahang M, Buras RR, Davoodi F, et al. 1,25-dihydroxyvitamin d3 receptor as a marker of human colon carcinoma cell line differentiation and growth inhibition. Cancer Res 1993;53:3712-18
   PubMed Web of Science ®Google Scholar
• Simboli-Campbell M, Narvaez CJ, Tenniswood M, et al. 1,25-Dihydroxyvitamin d3 induces morphological and biochemical markers of apoptosis in mcf-7 breast cancer cells. J Steroid Biochem Mol Biol 1996;58:367-76
   PubMed Web of Science ®Google Scholar
• Ylikomi T, Laaksi I, Lou YR, et al. Antiproliferative action of vitamin d. Vitam Horm 2002;64:357-406
   PubMed Web of Science ®Google Scholar
• Welsh J. Cellular and molecular effects of vitamin d on carcinogenesis. Arch Biochem Biophys 2012;523:107-14
   PubMed Web of Science ®Google Scholar
• Swami S, Krishnan AV, Feldman D. Vitamin d metabolism and action in the prostate: implications for health and disease. Mol Cell Endocrinol 2011;347:61-9
   PubMed Web of Science ®Google Scholar
• Banach-Petrosky W, Ouyang X, Gao H, et al. Vitamin d inhibits the formation of prostatic intraepithelial neoplasia in nkx3.1;pten mutant mice. Clin Cancer Res 2006;12:5895-901
   PubMed Web of Science ®Google Scholar
• Ahonen MH, Tenkanen L, Teppo L, et al. Prostate cancer risk and prediagnostic serum 25-hydroxyvitamin d levels (Finland). Cancer Causes Control 2000;11:847-52
   PubMed Web of Science ®Google Scholar
• Osborn JL, Schwartz GG, Smith DC, et al. Phase ii trial of oral 1,25-dihydroxyvitamin d (calcitriol) in hormone refractory prostate cancer. Urol Oncol 1995;1:195-8
   PubMedGoogle Scholar
• Muindi JR, Peng Y, Potter DM, et al. Pharmacokinetics of high-dose oral calcitriol: results from a phase 1 trial of calcitriol and paclitaxel. Clin Pharmacol Ther 2002;72:648-59
   PubMed Web of Science ®Google Scholar
• Marshall DT, Savage SJ, Garrett-Mayer E, et al. Vitamin d3 supplementation at 4000 international units per day for one year results in a decrease of positive cores at repeat biopsy in subjects with low-risk prostate cancer under active surveillance. J Clin Endocrinol Metab 2012;97:2315-24
   PubMed Web of Science ®Google Scholar
• Liu MM, Huang Y, Wang J. Developing phytoestrogens for breast cancer prevention. Anticancer Agents Med Chem 2012;12:1306-13
   PubMed Web of Science ®Google Scholar
• Nur Özten-Kandaş MCB. Chemoprevention of prostate cancer: natural compounds, antiandrogens, and antioxidants – in vivo evidence. J Carcinogenisis 2011;10:27
   PubMedGoogle Scholar
• Hamilton-Reeves JM, Rebello SA, Thomas W, et al. Effects of soy protein isolate consumption on prostate cancer biomarkers in men with hgpin, asap, and low-grade prostate cancer. Nutr Cancer 2008;60:7-13
   PubMed Web of Science ®Google Scholar
• Konijeti R, Henning S, Moro A, et al. Chemoprevention of prostate cancer with lycopene in the tramp model. Prostate 2010;70:1547-54
   PubMed Web of Science ®Google Scholar
• de Souza PL, Russell PJ, Kearsley JH, et al. Clinical pharmacology of isoflavones and its relevance for potential prevention of prostate cancer. Nutr Rev 2010;68:542-55
   PubMed Web of Science ®Google Scholar
• Society AC. Cancer facts and figures 2013. American Cancer Society; Atlanta, Ga: 2013
   Google Scholar
• Cazzaniga M, Bonanni B. Breast cancer chemoprevention: old and new approaches. J Biomed Biotechnol 2012;2012:985620
   PubMedGoogle Scholar
• Palozza P, Colangelo M, Simone R, et al. Lycopene induces cell growth inhibition by altering mevalonate pathway and ras signaling in cancer cell lines. Carcinogenesis 2010;31:1813-21
   PubMed Web of Science ®Google Scholar
• Teodoro AJ, Oliveira FL, Martins NB, et al. Effect of lycopene on cell viability and cell cycle progression in human cancer cell lines. Cancer Cell Int 2012;12:36
   PubMed Web of Science ®Google Scholar
• Qiu X, Yuan Y, Vaishnav A, et al. Effects of lycopene on protein expression in human primary prostatic epithelial cells. Cancer Prev Res (Phila) 2013;6(5):419-27
   PubMed Web of Science ®Google Scholar
• Shen J, Barrios RJ, Jaiswal AK. Inactivation of the quinone oxidoreductases nqo1 and nqo2 strongly elevates the incidence and multiplicity of chemically induced skin tumors. Cancer Res 2010;70:1006-14
   PubMed Web of Science ®Google Scholar
• Henderson CJ, Wolf CR. Disruption of the glutathione transferase pi class genes. Methods Enzymol 2005;401:116-35
   PubMed Web of Science ®Google Scholar
• Sporn MB, Liby KT. Is lycopene an effective agent for preventing prostate cancer? Cancer Prev Res (Phila) 2013;6:384-6
   PubMed Web of Science ®Google Scholar
• Ilic D, Misso M. Lycopene for the prevention and treatment of benign prostatic hyperplasia and prostate cancer: a systematic review. Maturitas 2012;72:269-76
   PubMed Web of Science ®Google Scholar
• Huang J, Plass C, Gerhauser C. Cancer chemoprevention by targeting the epigenome. Curr Drug Targets 2011;12:1925-56
   PubMed Web of Science ®Google Scholar
• Khan N, Adhami VM, Mukhtar H. Apoptosis by dietary agents for prevention and treatment of prostate cancer. Endocr Relat Cancer 2010;17:R39-52
   PubMed Web of Science ®Google Scholar
• Subramanian L, Youssef S, Bhattacharya S, et al. Resveratrol: challenges in translation to the clinic–a critical discussion. Clin Cancer Res 2010;16:5942-8
   PubMed Web of Science ®Google Scholar
• Aggarwal BB, Bhardwaj A, Aggarwal RS, et al. Role of resveratrol in prevention and therapy of cancer: preclinical and clinical studies. Anticancer Res 2004;24:2783-840
   PubMed Web of Science ®Google Scholar
• Scott E, Steward WP, Gescher AJ, et al. Resveratrol in human cancer chemoprevention–choosing the ‘right’ dose. Mol Nutr Food Res 2012;56:7-13
   PubMed Web of Science ®Google Scholar
• Yuan H, Young CY, Tian Y, et al. Suppression of the androgen receptor function by quercetin through protein-protein interactions of sp1, c-jun, and the androgen receptor in human prostate cancer cells. Mol Cell Biochem 2010;339:253-62
   PubMed Web of Science ®Google Scholar
• Nemeth K, Plumb GW, Berrin JG, et al. Deglycosylation by small intestinal epithelial cell beta-glucosidases is a critical step in the absorption and metabolism of dietary flavonoid glycosides in humans. Eur J Nutr 2003;42:29-42
   PubMed Web of Science ®Google Scholar
• McCann SE, Ambrosone CB, Moysich KB, et al. Intakes of selected nutrients, foods, and phytochemicals and prostate cancer risk in western New York. Nutr Cancer 2005;53:33-41
   PubMed Web of Science ®Google Scholar
• Zhang DD. The nrf2-keap1-are signaling pathway: the regulation and dual function of nrf2 in cancer. Antioxid Redox Signal 2010;13:1623-6
   PubMed Web of Science ®Google Scholar
• Kelloff GJ, Higley HR, Brawer MK, et al. Chemoprevention strategies in the prostate: an overview. Rev Urol 2002;4:69-77
   PubMedGoogle Scholar
• Shukla S, Gupta S. Dietary agents in the chemoprevention of prostate cancer. Nutr Cancer 2005;53:18-32
   PubMed Web of Science ®Google Scholar